Retatrutide
An investigational triple-receptor peptide showing the strongest weight reduction outcomes to date in clinical trials, prescribed under physician supervision at SSK Longevity in Newport Beach, California.
The Triple-Receptor Frontier of Metabolic Therapy
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors simultaneously: GLP-1, GIP, and glucagon. This triple-agonist design has produced the strongest mean weight reduction outcomes seen in any peptide clinical trial to date.
Retatrutide is currently investigational and is not FDA-approved for any indication. At SSK Longevity in Newport Beach, retatrutide may be prescribed under physician supervision in specific clinical circumstances, with comprehensive lab work, medical evaluation, and ongoing oversight by Dr. Sean Kelishadi, MD FACS and pharmacy supervision by Sherry Kelishadi, Pharm.D.
Why Triple-Receptor Activation Is the Frontier
Retatrutide's three-receptor design activates GLP-1, GIP, and glucagon pathways at once. Glucagon receptor activity, in particular, drives energy expenditure and fat oxidation in ways the GLP-1 and GIP pathways alone do not.
GLP-1 Activation
Slowed gastric emptying and central appetite suppression, the same mechanism behind semaglutide's clinical effect.
GIP Activation
Improved insulin sensitivity, glucose handling, and lipid metabolism — the same dual-receptor advantage as tirzepatide.
Glucagon Activation
Increased energy expenditure, hepatic fat oxidation, and basal metabolic rate, expanding the therapeutic mechanism beyond appetite alone.
Investigational Retatrutide, Compounded Under Pharm.D. Supervision
Retatrutide is currently investigational and not FDA-approved. Any retatrutide protocol at SSK Longevity Newport Beach is reviewed individually by Dr. Sean Kelishadi for medical appropriateness, with Sherry Kelishadi, Pharm.D. overseeing pharmacy compounding, dose pacing, and drug interaction screening.
Patients seeking retatrutide receive thorough informed-consent, lab work, and clinical evaluation before any vial is dispensed.
Individual results are not guaranteed and may vary from person to person.
- Personalized lab review and metabolic assessment
- Compounded under Pharm.D. supervision in Newport Beach
- Individualized dose protocols tailored to your physiology
- Drug interaction review before anything is dispensed
- Direct physician access throughout treatment
- Coordinated care with complementary protocols when appropriate
Peptides Considered Before Or Alongside Retatrutide
Patients pursuing retatrutide in Newport Beach often layer or transition between peer GLP-1-class peptides for sustained results, muscle preservation, and metabolic depth.
Peptide Therapy Considered Alongside Retatrutide
Retatrutide is rarely the whole protocol. SSK Longevity Newport Beach patients commonly layer peptide therapy alongside retatrutide for muscle preservation, recovery, and metabolic depth. Sherry Kelishadi, Pharm.D. coordinates every combined protocol individually before dispensing.
Tirzepatide
Dual-receptor (GLP-1, GIP) FDA-approved branded peer with established clinical track record. Most retatrutide patients have first tried tirzepatide.
Learn More →Semaglutide
Single-receptor (GLP-1) FDA-approved branded peer. The standard entry point for compounded GLP-1 therapy at SSK Longevity.
Learn More →CJC-1295 / Ipamorelin
Growth peptide stack used alongside retatrutide for muscle preservation, recovery, and longevity layering.
Learn More →Retatrutide Benefits at SSK Longevity in Newport Beach, CA
Retatrutide therapy at SSK Longevity in Newport Beach offers the strongest weight reduction outcomes seen in modern metabolic research, with phase 2 trial data exceeding 24 percent body weight reduction. As an investigational triple-agonist, every Retatrutide protocol is reserved for carefully selected adults across Newport Beach, Costa Mesa, Irvine, Laguna Beach, and Orange County who need deeper metabolic intervention than Semaglutide or Tirzepatide can provide. Below are the clinical effects Newport Beach Retatrutide patients consistently report.
Strongest Trial Outcomes To Date
Phase 2 trials report mean weight reduction exceeding 24% at higher doses — the strongest peptide outcomes seen in clinical research.
Triple Mechanism Of Action
Glucagon receptor activation drives metabolic rate and fat oxidation in addition to the appetite and insulin effects of GLP-1/GIP.
Improved Hepatic Markers
Trial data shows improvements in liver fat content and hepatic markers alongside weight reduction outcomes.
Insulin Sensitivity
Combined GIP and glucagon activity supports improved glucose handling and metabolic flexibility.
Sustained Cardiometabolic Benefit
Improvements in blood pressure, lipid panels, and inflammatory markers are common alongside weight reduction in clinical research.
Physician-Supervised Access
Retatrutide patients at SSK Longevity receive ongoing medical oversight, lab tracking, and Pharm.D.-supervised compounding.
Who Is The Right Candidate For Retatrutide?
Retatrutide at SSK Longevity Newport Beach is appropriate for adults seeking medically supervised peptide therapy with physician oversight, lab-driven protocol design, and Pharm.D.-supervised compounding. Patients pursuing this protocol typically fit one or more of the profiles below.
Conditions Treated Alongside Retatrutide in Newport Beach
Hormonal Imbalance
Insulin resistance and metabolic hormonal disruption addressed alongside retatrutide.
→
Fatigue & Low Energy
Metabolic burnout and energy regulation tied to insulin resistance and weight challenges.
→
Poor Muscle Recovery
Lean mass preservation during retatrutide-driven weight loss is a primary clinical concern.
→
Low Testosterone
Insulin resistance and low T frequently co-occur. Hormonal optimization pairs with metabolic protocols.
→How Retatrutide Therapy Is Designed at SSK Longevity
Comprehensive Consultation
Lab review, medical history, and informed-consent discussion with the SSK Longevity team in Newport Beach.
Personalized Protocol
Retatrutide dose, titration pacing, and complementary peptides calibrated to your physiology, goals, and trial-data context.
Pharmacist Compounding
Sherry Kelishadi, Pharm.D. oversees every retatrutide vial dispensed by SSK Longevity, with rigorous compounding and interaction screening.
Ongoing Clinical Oversight
Frequent follow-ups, lab rechecks, and dose adjustments calibrated to your response over time.
Retatrutide Safety, Investigational Status, and Contraindications
Retatrutide therapy under proper medical supervision has a well-characterized safety profile, but real considerations deserve direct discussion before any Newport Beach patient begins a protocol.
-
—
Investigational regulatory status Retatrutide is not FDA-approved for any indication. The long-term safety and efficacy profile is still being characterized. Patients must understand and accept this before treatment begins.
-
—
Pronounced gastrointestinal effects during titration GI burden tends to be more pronounced than with Tirzepatide due to the triple-receptor mechanism. Conservative dose pacing is essential.
-
—
Muscle preservation is critical The depth of weight loss creates significant risk of lean mass loss. Resistance training, adequate protein, and complementary peptides are integrated from day one.
-
—
Contraindicated in MTC or MEN2 history As with other GLP-1 agonists, Retatrutide is not appropriate for patients with personal or family history of medullary thyroid carcinoma or MEN2.
-
—
Glucagon component requires hepatic monitoring The glucagon receptor activity demands monitoring of liver function. Pre-existing hepatic conditions require careful evaluation.
-
—
Long-term sustainability and exit planning Given the depth of metabolic effect, exit strategy is discussed at the start of every protocol, never after the fact.
What patients actually say.
"After plateauing on tirzepatide, my SSK team walked me through retatrutide carefully — the informed-consent process was thorough and reassuring."
"What stood out was how cautious and individualized everything was. Lab work, dosing, follow-up — all calibrated to me specifically."
"I came to SSK because I wanted access under genuine medical oversight, not just a refill mill. They delivered exactly that."
From Our Founders
Retatrutide represents the frontier of metabolic peptide therapy. Because it is investigational, every patient who pursues it at SSK Longevity receives extensive informed consent, lab work, and clinical oversight. We do not prescribe retatrutide casually — we prescribe it thoughtfully.
Investigational peptides require even more rigorous pharmacy oversight than approved medications. Every retatrutide vial we dispense is reviewed for dose, drug interactions, and patient-specific factors. This is not a one-size-fits-all therapy.
Why Retatrutide Patients Trust SSK Longevity With Investigational Care
Retatrutide FAQ for Newport Beach & Orange County
Is retatrutide FDA-approved?
No. Retatrutide is currently investigational and is not FDA-approved for any indication. It may be prescribed under physician supervision in specific clinical circumstances, with full informed consent.
How does retatrutide compare to tirzepatide and semaglutide?
Retatrutide activates three receptors (GLP-1, GIP, glucagon), tirzepatide activates two (GLP-1, GIP), and semaglutide activates one (GLP-1). Trial data suggests retatrutide produces stronger mean weight loss outcomes than either.
What labs are required before starting?
Comprehensive metabolic panel, hemoglobin A1c, lipid panel, thyroid markers, hepatic markers, and other relevant labs are reviewed before initiation. Sean and Sherry tailor the workup to your medical history.
How long is a typical retatrutide protocol?
Protocol length is individualized. Because retatrutide is investigational, follow-up cadence is more frequent than with FDA-approved peptides — typically with rechecks at shorter intervals during titration.
What are the most common side effects?
Trials report nausea, gastrointestinal symptoms, and fatigue, particularly during dose titration. Glucagon-receptor activity may produce different side-effect patterns than GLP-1-only peptides.
Can I switch from tirzepatide to retatrutide?
Many SSK Longevity patients consider retatrutide after a tirzepatide plateau or when seeking deeper metabolic effect. Transition is evaluated individually with full informed consent.
Is retatrutide layered with peptide therapy?
Yes — patients often combine retatrutide with peptides like CJC-1295/Ipamorelin for muscle preservation. Layering is always reviewed by Sherry Kelishadi, Pharm.D. before dispensing.
Where is SSK Longevity located?
SSK Longevity is in Newport Beach, California, at 500 Superior Avenue, Suite 340 — serving patients across Orange County including Costa Mesa, Irvine, Huntington Beach, and Laguna Beach.
Treatments Layered With Retatrutide at SSK Longevity
Medical Weight Loss
Comprehensive medically supervised weight management combining peptides, metabolic care, and lab oversight.
→
Metabolic Performance Optimization
Lab-driven metabolic optimization protocols layered with retatrutide for deeper, sustained results.
→
Peptide Therapy for Longevity
Targeted peptide protocols layered with retatrutide for muscle preservation and longevity.
→
Hormone Replacement Therapy
Hormonal optimization commonly stacked with metabolic peptides for integrated longevity care.
→Retatrutide is currently investigational and is not FDA-approved for any indication. Retatrutide may be used under physician supervision in specific clinical circumstances and is not an FDA-approved formulation. The information on this page is for educational purposes only and does not constitute medical advice. Treatment requires physician evaluation, comprehensive laboratory testing, and ongoing clinical oversight. Compounded peptide therapy is generally an out-of-pocket service and is not typically covered by insurance. Payment options and financing are available. Individual results are not guaranteed and may vary from person to person. All treatments are administered under the supervision of a licensed physician.